Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpiN-Tec MCTI UFMG Vaccine Booster for COVID-19
NCT07134725Phase 2Completed
- Sponsor
- Universidade Federal de Minas Gerais
- Start
- Nov 2022
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SpiN-Tec in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Universidade Federal de Minas Gerais. Primary endpoints: Safety and reactogenicity for EAG and EAIE at 360 days, Define a safe and immunogenic dose of SpiN-Tec MCTI UFMG and 1 more. Started Nov 2022; status: completed.
02
Drugs
SpiN-Tec
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07134725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134725.